c patients in IDEAL 2РFukuoka et al 2003; Kris et al 2003РErlotinib: awaiting approval ?for the treatment of ?advanced NSCLCРResponse rate, % ?Disease control rate, %?Median survival, months ?1-year survival, %Рn=57?12.3 ?50.9?8.4?40РPerez-Soler et al 2003РOther EGFR-targeted therapies ?under clinical developmentРKРKРKРEMD72000Рh-R3РABX-EGFРPKI-1066РCI-1033РEKB-569РmAbsРTKIsРSummary of current ?EGFR-targeted treatment optionsРTo date, two EGFR-targeted therapies have been approved for the treatment of patients with advanced or metastatic CRC (cetuximab) or NSCLC (gefitinib)?Approval of erlotinib for the treatment of advanced NSCLC is expected in 2004?Several other EGFR-targeted therapies are undergoing clinical development, with the majority showing some activity in a range of solid tumors
全文预览
